Bluejay Diagnostics filings document the company’s medical diagnostics business, Nasdaq-listed common stock, and disclosures tied to development of the Symphony™ near-patient testing platform. Form 8-K reports cover corporate updates, financial condition items, Regulation FD disclosures, SYMON clinical-study updates, conference-related product disclosures, manufacturing readiness, and capitalization matters involving warrants and private placements.
The company’s proxy materials describe annual meeting proposals, voting procedures, board and governance matters, and stockholder approval topics. Bluejay’s filings also identify it as an emerging growth company and include formal disclosures on material agreements, registered securities, risk-relevant development activities, and capital-structure changes such as reverse stock splits and warrant exercises.
Bluejay Diagnostics, Inc. registers 11,223,665 shares of common stock for resale by selling stockholders, comprised of shares issuable upon exercise of Pre-Funded Warrants, Series G Warrants, Series H Warrants and Placement Agent Warrants issued June 5, 2026. The company is not selling shares and will not receive proceeds from resales.
The issuer will receive net proceeds only if the Warrants are exercised for cash; the prospectus notes we will receive the net proceeds of any Warrants exercised for cash. The registration limits certain exercises by holders under 4.99% or 9.99% beneficial ownership caps and states shares outstanding were 1,034,715 as of June 17, 2026.
Bluejay Diagnostics, Inc. files a registration to permit resale of up to 11,223,665 shares of its common stock by identified selling stockholders. The shares consist of common stock issuable upon exercise of pre-funded warrants, Series G and H warrants, and placement agent warrants issued June 5, 2026.
The Company is not selling any shares under this prospectus and will not receive proceeds from resales; Bluejay will receive the net proceeds only if the warrants are exercised for cash. The prospectus covers resale methods, selling limits (including 4.99%/9.99% ownership caps), and plan-of-distribution alternatives.
Bluejay Diagnostics, Inc. held its 2026 annual stockholder meeting and approved several key proposals. Stockholders adopted an amendment to the 2021 Stock Plan, increasing the shares reserved for equity awards by 600,000, bringing the total plan reserve to 600,061 shares.
They also approved an amendment to the certificate of incorporation authorizing a potential reverse stock split at a ratio between 1-for-2 and 1-for-20, to be implemented at the board’s discretion no later than June 9, 2027. The board currently has no intention to implement the split and the stock was trading at $4.50 per share, in compliance with Nasdaq’s $1.00 minimum bid requirement.
All five incumbent directors were re-elected, and Wolf & Company, P.C. was ratified as independent auditor for the year ending December 31, 2026. At the record date, there were 1,034,715 shares outstanding, with 414,092 shares represented at the meeting, constituting a quorum.
Bluejay Diagnostics, Inc. completed a private placement of common stock and warrants generating gross proceeds of $8.5 million and approximately $7.7 million in net proceeds. Investors purchased 3,655,917 shares of common stock (or pre-funded warrants) plus Series G and Series H warrants to buy up to 3,655,917 shares each.
The securities were priced at $2.325 per share (or pre-funded warrant) with accompanying warrants, and the Series G and H warrants carry an exercise price of $2.075 per share. Bluejay plans to use the funds for FDA approval efforts, related clinical studies, other research and development, and general working capital.
Bluejay Diagnostics, Inc. Schedule 13G reports that three reporting persons — Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC — may be deemed to beneficially own 114,840 shares of common stock, representing 9.99% of the class based on 1,034,715 shares outstanding as of May 4, 2026. The filing states these shares are issuable upon exercise of a warrant held by Intracoastal and describes multiple additional warrant tranches that are subject to exercise restrictions and resale‑registration conditions.
Northstrive Fund II LP and Braeden Lichti have fully exited their position in Bluejay Diagnostics, Inc. common stock. In Amendment No. 1 to their Schedule 13G, they report that as of June 2, 2026, they beneficially own 0 shares, representing 0.00% of the company’s common stock. The amendment states that all previously held shares were sold and that they have ceased to be beneficial owners of more than five percent of the outstanding common stock. This amendment is identified as a final, or “exit,” filing for both reporting persons.
Bluejay Diagnostics, Inc. (BJDX) now has one less significant shareholder after Braeden Lichti and Northstrive Fund II LP fully exited their position in its common stock. As of June 2, 2026, both reporting persons beneficially own 0 shares, representing 0.00% of the outstanding common stock.
The amendment notes that all previously held shares of Bluejay Diagnostics’ common stock were sold, and the filers ceased to be beneficial owners of more than five percent of the company’s shares. This amendment is described as the final amendment and an exit filing for both reporting persons.
Bluejay Diagnostics, Inc. entered a material definitive agreement with Argonaut Manufacturing Services to provide U.S.-based manufacturing and related services for Bluejay’s Symphony™ platform IL-6 testing products. Argonaut will support planning, engineering, sourcing, supply chain management, formulation, filling, finishing, quality control testing, capital equipment procurement, storage, delivery, and distribution under purchase orders issued over time.
The partnership is intended to establish scalable domestic manufacturing, reduce reliance on overseas production, and strengthen Bluejay’s future commercial infrastructure, including broader U.S. product distribution and greater supply chain resilience. The collaboration supports Bluejay’s ongoing clinical development programs and future commercialization plans for its near-patient diagnostic solutions.
Bluejay Diagnostics director Wurth Douglas Clark bought additional common stock in the company. On March 14, 2026, he purchased 12,500 shares of Bluejay Diagnostics, Inc. common stock from the issuer in a private placement at $2.00 per share.
Following this transaction, his reported holdings increased to 12,608 shares of common stock, which includes 34 shares held by Wurth Holdings LLC, an entity he controls.
Bluejay Diagnostics, Inc. director and President/CEO Indranil Dey bought additional company stock. On March 14, 2026, he purchased 12,500 shares of common stock from the company in a private placement at $2.00 per share, bringing his direct holdings to 12,522 shares. He also indirectly owns 127 shares held by Lana Management & Business Research International, LLC, over which he has voting and dispositive power.